The New Jersey Innovation Institute’s Biopharma Division, which includes BioCentriq, its cell and gene therapy development and manufacturing center, has welcomed Beth Thompson-Webb to its advisory committee.  Thompson-Webb has more than two decades of experience in life sciences …

Dr. Haro Hartounian is senior vice president and general manager of the Biopharma Division of the New Jersey Innovation Institute (NJII). The division, founded in 2015, includes a state-of-the-art cell and gene therapy development center …

NJII announces that qualification and validation of its clinical manufacturing facility for cell and gene therapies is underway, and the name of the center will be BioCentriq. May 4, 2020:  Newark, N.J. – Today the …

The New Jersey Innovation Institute’s Biopharma Division welcomed Kevin D. Belfield to its advisory committee. The committee is made up of executives from leading pharmaceutical and biotech organizations, and Dr. Belfield — a renowned scientist …

NEWARK, NJ, March 10, 2020 – The New Jersey Innovation Institute’s (NJII) Biopharma division is pleased to announce the formation of their advisory committee which includes experts from across the industry. The committee will meet quarterly and …

It is evident that the cell and gene therapy sectors are growing faster than the field of available talent, pressuring start-ups and established players alike. That was the key driver for the Talent Development Ideation …

NEWARK, NJ, October 8, 2019 – Donald H. Sebastian, NJII CEO and president, Tomas Gregorio, senior vice president NJII healthcare division and Haro Hartounian, senior executive director NJII biotechnology and pharmaceutical innovation have been named to …

NEWARK, NJ, March 19, 2019 – New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) Corporation, has signed an Industry Participation Agreement with Pall Corporation (Pall) to support the development of its Biopharmaceutical …